TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00645957

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: red rubber drain
Description: incision and drainage of infection and placement of a red rubber drain
Study: NCT00571168

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules on day 1-4
Study: NCT03753113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Herbal Solution
Description: Use Topical Herbal Solution every day in scalp hair loss areas for 36 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Minoxidil 5%
Description: Use Minoxidil 5% solution every day in scalp hair loss areas for 36 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Minoxidil 5%
Description: Use Minoxidil 5% solution every day in scalp hair loss areas for 36 weeks.
Study: NCT02252939

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: X-Ray
Description: X-ray as part of standard care
Study: NCT04017481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: The intervention intends to change the cortical plasticity in specific cortical areas. rTMS is a non-invasive exogenous neuromodulation technique that uses repetitive magnetic pulses administered in a specific area of the head in order to influence the connectivity of the underlying brain area.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: The intervention intends to change the cortical plasticity in specific cortical areas. rTMS is a non-invasive exogenous neuromodulation technique that uses repetitive magnetic pulses administered in a specific area of the head in order to influence the connectivity of the underlying brain area.
Study: NCT01315561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture, injection
Description: MSAT and intramuscular injections of diclofenac(NSAID)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture, injection
Description: MSAT and intramuscular injections of diclofenac(NSAID)
Study: NCT03353519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary care model
Description: Specifically, the intervention will comprise the following components:~1. Structured review of patient needs;~2. A self-management programme (MLAS) for stroke survivors and their carers;~3. A direct point of contact for stroke survivors and carers at the GP surgery;~4. Optimised communication between General Practice staff and specialist services;~5. Service mapping for stroke related needs;~6. Training for General Practice staff.
Study: NCT03666364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sperm preparation for ICSI
Description: A new protocol for sperm preparation for ICSI cycles with teratozoospermia in over 35 years old women
Study: NCT03859362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem Injection
Description: 1 g of ertapenem q24h, 30 min infusion
Study: NCT01710813

Intervention type: BIOLOGICAL
Intervention: alglucosidase alfa
Description: Alglucosidase alfa IV infusion of 20 mg/kg; qow
Study: NCT05388292

Intervention type: OTHER
Group type: OTHER
Intervention: Emergency triage decision support system
Description: Evaluating the impact of the developed Emergency Triage Decision Support System on triage management
Study: NCT03304249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iAmHealthy Healthy Lifestyles Program
Description: iAmHealthy is behavioral intervention focused on nutrition, behavior and physical activity that engages parents and children in treatment using mobile health (mHealth) technology. Meetings are approximately one hour. Participants will log in for 8 weekly group sessions, followed by 6 monthly sessions.
Study: NCT04017481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG guided Neurofeedback (NFB)
Description: The intervention intends to change the cortical plasticity in specific cortical areas. The NFB is a non-invasive endogenous technique that seeks the self-regulation of cortical activity through the information represented in a videogame which is used to interact with the subject.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG guided Neurofeedback (NFB)
Description: The intervention intends to change the cortical plasticity in specific cortical areas. The NFB is a non-invasive endogenous technique that seeks the self-regulation of cortical activity through the information represented in a videogame which is used to interact with the subject.
Study: NCT02522702

Intervention type: OTHER
Intervention: Photography of polyps, resection of polyps
Description: Ther is no study specific intervention. Still images will be taken if polyps are found in the colon. Polyps will then be resected routinely.
Study: NCT00575627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-Interferon alpha2a plus Ribavirin
Description: Peg-Interferon alpha2a: 180 micrograms per week Ribavirin:100-1200 mg/daily
Study: NCT03304249

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Newsletter
Description: Weight loss materials delivered via a newsletter. Each newsletter will cover nutritional, exercise, and behavioral suggestions to improve the child's health. The newsletter will be sent in the mail once a month for 8 months.
Study: NCT04580992

Intervention type: DRUG
Intervention: Ajmaline
Description: Ajmaline administration
Study: NCT03008356

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine 1000 mg twice daily
Description: Oral L-carnitine to be taken twice daily for 8 weeks
Study: NCT01039103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-liposomal prednisolone sodium phosphate
Description: PEG-liposomal prednisolone sodium phosphate 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
Study: NCT03008356

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine 1000 mg twice daily
Description: Oral L-carnitine to be taken twice daily for 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly health coaching calls
Description: Weekly health coaching calls lasting 10-15 minutes
Study: NCT01039103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 1 g, IV, infusion over 2 hours on days 1, 2 and 3
Study: NCT02538354

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation
Description: Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation
Description: Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks
Study: NCT03008356

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Study: NCT01258504

Intervention type: DRUG
Intervention: St. Johns Wort
Description: * Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19.~* Administration of SJW: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20

Intervention type: DRUG
Intervention: St. Johns Wort
Description: * Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19.~* Administration of SJW: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20
Study: NCT00764595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Imatinib mesylate is administered as oral dose of 400 mg/d once daily after meal until 3 years after enrollment of the last patient.
Study: NCT04096274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leadership for Organization Change and Implementation (LOCI)
Description: LOCI is a multicomponent implementation strategy that engages organizational executives and first-level leaders (i.e., those who administratively supervise clinicians) to build an organizational climate to support the implementation of a focal evidence-based practice (EBP) with fidelity. In this study, the focal EBP is the OQ-A system. LOCI includes two overarching components: (1) monthly organizational strategy meetings between executives and LOCI consultants/trainers to develop and embed policies, procedures, and practices that support implementation of a focal EBP, and (2) training and coaching for first-level leaders, to develop their skills in leading implementation. The aim of these components is to develop an organizational implementation climate in which clinicians' perceive that use of the OQ-A with high fidelity is expected, supported, and rewarded.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training and Technical Assistance Only
Description: All leaders and clinicians in participating clinics will receive standardized OQ-A training and technical assistance provided by the OQ-A purveyor organization. This includes an initial, 6-hr, in-person OQ-A training; two, live, virtual, 1-hr booster trainings, offered 3 and 5 months after the initial training; and, year-round technical assistance from the OQ-A purveyor organization. Technical assistance includes virtual training sessions, online library of training videos, and customer care representative for technical support.~In addition, to encourage participation in the study, a set of four 1-hr, web-based general leadership seminars will be offered to leaders in the control condition. These will cover topics ranging from effective leadership, to giving effective feedback.
Study: NCT04435717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1
Description: Tocilizumab 20 MG/ML Intravenous (one dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses)
Description: Tocilizumab 20 MG/ML Intravenous ( two doses)
Study: NCT01696513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suction
Study: NCT04096274

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training and Technical Assistance Only
Description: All leaders and clinicians in participating clinics will receive standardized OQ-A training and technical assistance provided by the OQ-A purveyor organization. This includes an initial, 6-hr, in-person OQ-A training; two, live, virtual, 1-hr booster trainings, offered 3 and 5 months after the initial training; and, year-round technical assistance from the OQ-A purveyor organization. Technical assistance includes virtual training sessions, online library of training videos, and customer care representative for technical support.~In addition, to encourage participation in the study, a set of four 1-hr, web-based general leadership seminars will be offered to leaders in the control condition. These will cover topics ranging from effective leadership, to giving effective feedback.
Study: NCT00705211

Intervention type: DRUG
Intervention: Ezetimibe
Description: Ezetimibe, 10-mg tablets,

Intervention type: DRUG
Intervention: Ezetimibe + other lipid-lowering medication(s)
Description: Ezetimibe, 10-mg tablets, other lipid-lowering medication(s) as prescribed by attending physician
Study: NCT00187421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indocyanine green intraoperative angiogram and transit-time flowmetry
Description: ICG graft angiography following each distal anastomosis, and imaging of proximal anastomoses after all grafts completed.~transit time flowmetry performed on all grafts after all grafts completed.
Study: NCT02204150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI Capsule
Description: Imaging of the esophagus using the OFDI Capsule and system
Study: NCT00515801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glibenclamide
Description: glibenclamide 15 mg single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules, single dose
Study: NCT03574090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Clavulanate
Description: To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiological Saline
Description: To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physiological Saline
Description: To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
Study: NCT01208350

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Monthly weigh-ins for 6 months without financial incentives associated with weight loss, and follow-up weigh-in at 9 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based payout
Description: Monthly weigh-ins for 6 months where five sequential participants, randomized to this condition, will be joined into virtual groups where individual rewards for weight loss are dependent on the weight loss of others in the group, with follow-up weigh in at 9 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual payout
Description: Monthly weigh-ins for 6 months and if monthly goals are met, participants receive payout at the end of the month, with follow-up weigh-in at 9 months
Study: NCT00119535

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Implementation of Proactive Diabetes Eye Care Program
Study: NCT02366611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
Study: NCT01050309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hexaminolevulinate (HAL)
Description: Intravenous dose of HAL 0.4 mg/kg including 100 nCi (3.7 kBq) 14C infused over a one hour period. A vaginal dose HAL 150 mg including 13,9 kBq of 14C HAL will be administered for 7 hours. Following a colon cleaning, 100mg HAL enema including 14,8 kBq of 14C will be instilled for 30 minutes in colon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hexaminolevulinate (HAL)
Description: Intravenous dose of HAL 0.4 mg/kg including 100 nCi (3.7 kBq) 14C infused over a one hour period. A vaginal dose HAL 150 mg including 13,9 kBq of 14C HAL will be administered for 7 hours. Following a colon cleaning, 100mg HAL enema including 14,8 kBq of 14C will be instilled for 30 minutes in colon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hexaminolevulinate (HAL)
Description: Intravenous dose of HAL 0.4 mg/kg including 100 nCi (3.7 kBq) 14C infused over a one hour period. A vaginal dose HAL 150 mg including 13,9 kBq of 14C HAL will be administered for 7 hours. Following a colon cleaning, 100mg HAL enema including 14,8 kBq of 14C will be instilled for 30 minutes in colon
Study: NCT02728193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MWV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEI
Description: Percutaneous ethanol injection
Study: NCT04098770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Adoptive Immune Therapy
Description: A dose (2-3 times) of AAIT was added on conventional treatment for advanced AIDS patients
Study: NCT00985062

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mild Ovarian Stimulation Treatment
Description: Administration of a fixed dose of 150 IU/day rFSH s.c. (Puregon® NV Organon, Oss, The Netherlands) from cycle day 5 onwards. As soon as the leading follicle reached a diameter of 14mm, a GnRH-antagonist (Orgalutran®, NV Organon, Oss, The Netherlands) was administered at 0.25 mg/day s.c.. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Ovarian Stimulation Treatment
Description: Administration of GnRH agonist Triptorelin (Decapeptyl®, Ferring BV, Hoofddorp, The Netherlands) at 0.1 mg/day s.c., starting on cycle day 21 of the menstrual cycle preceding the actual stimulation cycle. After two weeks of the GnRH regimen, co-treatment with rFSH 225 IU/day s.c. (Puregon®, NV Organon, Oss, The Netherlands) was initiated. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered
Study: NCT03746704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr˗DFO˗REGN3504
Description: 89Zr˗DFO˗REGN3504
Study: NCT02146612

Intervention type: OTHER
Intervention: Amino Acid Supplement Group
Description: Group receiving nutritional supplement
Study: NCT04438473

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pectin-supplemented enteral nutrition feeding
Description: sequential supplementation with combination of 90ml pectin and 500ml enteral nutrition formula for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: enteral nutrition feeding
Description: standard formula enteral nutrition feeding without pectin for 7 days
Study: NCT00290615

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT02222207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib, ophthalmic oily suspension (BAY73-4506)
Description: Subjects receive Regorafenib as eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib, ophthalmic oily suspension (BAY73-4506)
Description: Subjects receive Regorafenib as eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib, ophthalmic oily suspension (BAY73-4506)
Description: Subjects receive Regorafenib as eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib, ophthalmic oily suspension (BAY73-4506)
Description: Subjects receive Regorafenib as eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib, ophthalmic oily suspension (BAY73-4506)
Description: Subjects receive Regorafenib as eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib, ophthalmic oily suspension (BAY73-4506)
Description: Subjects receive Regorafenib as eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib, ophthalmic oily suspension (BAY73-4506)
Description: Subjects receive Regorafenib as eye drops

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham IVT
Description: Sham injections

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham IVT
Description: Sham injections

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham IVT
Description: Sham injections

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham IVT
Description: Sham injections

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham IVT
Description: Sham injections

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham IVT
Description: Sham injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Subjects receive Ranibizumab as intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops
Study: NCT01696513

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcision
Study: NCT02300298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel
Study: NCT04314921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga trainings
Description: 10-week yoga sessions, 2 times per week, 90 min per session.
Study: NCT01982292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLX030 (serelaxin)
Description: RLX030 (serelaxin) was administered according to a weight-range adjusted dosing regimen at a nominal dose of 30 μg/kg/day as a continuous IV infusion for 48 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of serelaxin was administered as a continuous IV infusion for 48 hours.
Study: NCT04129281

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Surgery acconding to clinical practice
Study: NCT03258528

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: positioning
Description: Positioning neonates for 6 hours either in right lateral position or supine position

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: positioning
Description: Positioning neonates for 6 hours either in right lateral position or supine position
Study: NCT02586675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen will be taken orally once daily on a continuous daily schedule (e.g., days 1-28 of each 28 day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib (LEE011) will be taken orally once daily on days 1-21 of each 28 day cycle. Days 22-28 will be a rest period from dosing with Ribociclib. In the continuous cohort, 400 mg ribociclib will be given daily (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin will be given as an injectable subcutaneous implant on day 1 of every 28 day cycle. This will be given in pre-menopausal and peri-menopausal women.
Study: NCT04500977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: leadership empowerment
Description: In the leadership program, women were taught more about the manner in which to bring about a change in one's health by adapting a healthy life style, leadership and facilitation skills and the development, implementation and evaluation process required to conduct a community program that will impact society. Women learned how to map needs and resources, define goals and objectives, develop, implement and evaluate a community based program.
Study: NCT03108313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aloe vera toothpaste
Description: herbal toothpaste used to decrease salivary streptococcus bacterial count